Mark C. Poznansky, M.D., Ph.D.
Founder and Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital (MGH)
Dr. Poznansky is an associate professor at Harvard Medical School and a research scholar and attending physician in Transplant Infectious Diseases Medicine at Massachusetts General Hospital (MGH). He serves on the Commercialization Council at Partners Healthcare and is the scientific founder of several biotech companies, including Vicapsys. Dr. Poznansky founded the MGH Vaccine and Immunotherapy Center (VIC) ten years ago with the mission to accelerate the development of broadly applicable, safe, and cost-effective vaccines and immunotherapies for cancer, infectious diseases, and type 1 diabetes (T1D). The scientific teams at VIC work at the interface between scientific discovery and medical product development, and the focus of one program is on the transplantation of human stem cell derived Beta cells to provide dynamic insulin replacement in people with T1D, without immunosuppression.
As active members of the Breakthrough T1D Beta Cell Replacement Consortium, Dr. Poznansky and his team have contributed significantly to the development of encapsulation therapy. With support from Breakthrough T1D, this team continues to explore and optimize using CXCL12, which is naturally secreted by our immune system, to protect implanted beta cells against inflammation and immune attack in encapsulation systems without the use of immune suppressive drugs. Dr. Poznansky holds a doctoral degree from Cambridge University and a medical degree from the University of Edinburgh.
Cocktail and hors d’oeuvres reception. Space is limited. Kindly reply by Thursday, November 7, 2019 online at https://jdrf-ne.org/SpeakerSeriesNov2019. You may also contact the Breakthrough T1D office at 781-431-0700 or dgaboury@BreakthroughT1D.org with any questions.
Please view and download the invitation here.
The Bostonian Boston
Valet parking will be available at the hotel for $25.
26 North Street
Boston, MA 02109
